LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 169

Search options

  1. Article ; Online: Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?

    Trkulja, Vladimir

    British journal of clinical pharmacology

    2022  Volume 88, Issue 7, Page(s) 3539–3541

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/drug therapy ; Humans ; SARS-CoV-2 ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2022-03-02
    Publishing country England
    Document type Letter
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15283
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Fluvoxamine for COVID-19 ICU patients?

    Trkulja, Vladimir

    British journal of clinical pharmacology

    2022  Volume 88, Issue 5, Page(s) 2454–2455

    MeSH term(s) COVID-19/drug therapy ; Fluvoxamine/therapeutic use ; Humans ; Intensive Care Units ; Serotonin Uptake Inhibitors
    Chemical Substances Serotonin Uptake Inhibitors ; Fluvoxamine (O4L1XPO44W)
    Language English
    Publishing date 2022-02-07
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15166
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Why we should not recommend or offer fluvoxamine to COVID-19 patients?

    Trkulja, Vladimir

    European journal of clinical pharmacology

    2022  Volume 79, Issue 2, Page(s) 321–322

    MeSH term(s) Humans ; Fluvoxamine/therapeutic use ; COVID-19 Drug Treatment ; COVID-19 ; Patients
    Chemical Substances Fluvoxamine (O4L1XPO44W)
    Language English
    Publishing date 2022-12-23
    Publishing country Germany
    Document type Letter ; Comment
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-022-03447-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Fluvoxamine for COVID-19 outpatients: For the time being, we might prefer to curb our optimism.

    Trkulja, Vladimir

    British journal of clinical pharmacology

    2022  Volume 88, Issue 10, Page(s) 4654–4656

    MeSH term(s) COVID-19/drug therapy ; Depressive Disorder ; Fluvoxamine/therapeutic use ; Humans ; Outpatients
    Chemical Substances Fluvoxamine (O4L1XPO44W)
    Language English
    Publishing date 2022-07-13
    Publishing country England
    Document type Letter
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15451
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use.

    Trkulja, Vladimir

    The Journal of infection

    2022  Volume 86, Issue 2, Page(s) 154–225

    MeSH term(s) Humans ; Fluvoxamine ; Outpatients ; COVID-19 ; COVID-19 Drug Treatment ; Double-Blind Method
    Chemical Substances Fluvoxamine (O4L1XPO44W)
    Language English
    Publishing date 2022-11-25
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 424417-5
    ISSN 1532-2742 ; 0163-4453
    ISSN (online) 1532-2742
    ISSN 0163-4453
    DOI 10.1016/j.jinf.2022.11.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.

    Trkulja, Vladimir

    European journal of clinical pharmacology

    2021  Volume 77, Issue 6, Page(s) 935–937

    MeSH term(s) Adenosine Monophosphate/administration & dosage ; Adenosine Monophosphate/analogs & derivatives ; Airway Management/methods ; Alanine/administration & dosage ; Alanine/analogs & derivatives ; Antiviral Agents/administration & dosage ; COVID-19/diagnosis ; COVID-19/drug therapy ; COVID-19/mortality ; COVID-19/physiopathology ; Disease Progression ; Humans ; Hypoxia/etiology ; Hypoxia/therapy ; Mortality ; Patient Selection ; Pneumonia, Viral/etiology ; Pneumonia, Viral/physiopathology ; Pneumonia, Viral/therapy ; Randomized Controlled Trials as Topic ; Respiratory Insufficiency/blood ; Respiratory Insufficiency/etiology ; Respiratory Insufficiency/therapy ; SARS-CoV-2 ; Time-to-Treatment ; Treatment Outcome
    Chemical Substances Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Language English
    Publishing date 2021-01-06
    Publishing country Germany
    Document type Letter
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-020-03085-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Moderating effect of obesity on clinical outcomes in NOAC-treated atrial fibrillation patients or just an effect of obesity?

    Trkulja, Vladimir

    International journal of cardiology

    2020  Volume 312, Page(s) 109

    MeSH term(s) Anticoagulants/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Body Mass Index ; Humans ; Obesity/epidemiology ; Vitamin K
    Chemical Substances Anticoagulants ; Vitamin K (12001-79-5)
    Language English
    Publishing date 2020-06-03
    Publishing country Netherlands
    Document type Letter ; Comment
    ZDB-ID 779519-1
    ISSN 1874-1754 ; 0167-5273
    ISSN (online) 1874-1754
    ISSN 0167-5273
    DOI 10.1016/j.ijcard.2020.03.070
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study.

    Trkulja, Vladimir / Kodvanj, Ivan

    European journal of clinical pharmacology

    2023  Volume 79, Issue 5, Page(s) 643–655

    Abstract: Purpose: To assess the effect of exposure to fluvoxamine around the COVID-19 diagnosis on subsequent hospitalizations and mortality in COVID-19 outpatients in a real-life setting.: Methods: Using nationwide administrative data, we identified adult ... ...

    Abstract Purpose: To assess the effect of exposure to fluvoxamine around the COVID-19 diagnosis on subsequent hospitalizations and mortality in COVID-19 outpatients in a real-life setting.
    Methods: Using nationwide administrative data, we identified adult COVID-19 outpatients diagnosed up to August 15, 2021 and conducted two cohort studies. Study 1 included subjects prescribed fluvoxamine around the index COVID-19 diagnosis (Cohort A), their peers suffering similar psychiatric difficulties but not prescribed fluvoxamine (Cohort B) and those free of psychiatric difficulties/treatments (Cohort C). Study 2 included subjects prescribed fluvoxamine (Cohort Fluvoxamine) and their peers prescribed paroxetine (Cohort Paroxetine). Cohorts were mutually exactly matched and incidence of COVID-19-related hospitalization, 30-day all-cause hospitalization and of COVID-19-related mortality was estimated.
    Results: Of the 416,030 first-episode outpatients, Study 1 included 1016 Cohort A, 95,984 Cohort B and 275,804 Cohort C patients. Matched Cohort A (n = 749) vs. Cohort B (n = 31,336) relative risks (95%CI/CrI), frequentist and Bayes with skeptical, otpimistic and pesimistic priors, were COVID-related hospitalization 1.37 (0.56-3.33), 1.15 (0.55-2.11), 1.03 (0.56.1.96) and 1.43 (0.63-2.94), respectively; 30-day all-cause hospitalization 1.88 (0.76-4.67), 1.76 (1.39-2.25), 1.76 (1.39-2.24) and 1.86 (1.43-2.38), respectively; COVID-19-related mortality 0.73 (0.35-1.55), 0.93 (0.53-1.76), 0.79 (0.40-1.54) and 0.88 (0.37-2.11), respectively. Matched Cohort A vs. C (866 vs. 222,792) comparison yielded similar estimates, as did the matched Cohort Fluvoxamine vs. Paroxetine comparison in Study 2 (344 of 994 matched to 535 of 1796 patients).
    Conslusion: Outpatients prescribed fluvoxamine around the time of COVID-19 diagnosis were not at a reduced risk of hospitalizations and mortality compared to their non-prescribed peers.
    MeSH term(s) Outpatients ; Humans ; Fluvoxamine/therapeutic use ; Drug Prescriptions/statistics & numerical data ; Practice Patterns, Physicians'/statistics & numerical data ; COVID-19/diagnosis ; COVID-19/epidemiology ; Cohort Studies ; Selective Serotonin Reuptake Inhibitors/therapeutic use ; Drug Repositioning ; Paroxetine/therapeutic use ; Male ; Female ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged ; Aged, 80 and over
    Chemical Substances Fluvoxamine (O4L1XPO44W) ; Selective Serotonin Reuptake Inhibitors ; Paroxetine (41VRH5220H)
    Language English
    Publishing date 2023-03-24
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-023-03479-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: In medical research, what appears to be intuitive and sensible might be erroneous: percent change from baseline.

    Trkulja, Vladimir / Hrabač, Pero

    Croatian medical journal

    2021  Volume 61, Issue 6, Page(s) 569–573

    MeSH term(s) Biomedical Research ; Humans
    Language English
    Publishing date 2021-01-07
    Publishing country Croatia
    Document type Journal Article
    ZDB-ID 1157623-6
    ISSN 1332-8166 ; 0353-9504
    ISSN (online) 1332-8166
    ISSN 0353-9504
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Association between serological indicators of past contacts with Herpesviridae and a slower resolution of chronic spontaneous urticaria in children.

    Čavčić, Anamarija / Đaković Rode, Oktavija / Trkulja, Vladimir

    Croatian medical journal

    2023  Volume 64, Issue 2, Page(s) 67–74

    Abstract: Aim: To evaluate the relationship between serological indicators of Herpesviridae infection and evolution of symptoms in children with chronic spontaneous urticaria (CSU).: Methods: In this observational study, consecutive children with CSU underwent, ...

    Abstract Aim: To evaluate the relationship between serological indicators of Herpesviridae infection and evolution of symptoms in children with chronic spontaneous urticaria (CSU).
    Methods: In this observational study, consecutive children with CSU underwent, at presentation, clinical and laboratory work-up, autologous serum skin test (ASST) to identify autoimmune urticaria (CAU), disease severity assessment (urticaria activity score 7, UAS7), serological diagnostics for Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpes virus-6 (HHV-6), and parvovirus B19, as well as for Mycoplasma pneumoniae and Chlamydia pneumoniae. Children were re-assessed at 1, 6, and 12 months after the commencement of antihistamine/antileukotriene treatment.
    Results: None of the 56 included children had an acute CMV/EBV or HHV-6 infection, but 17 (30.3%) had IgG antibodies against CMV, EBV, or HHV-6 (five were also seropositive for parvovirus B19); 24 (42.8%) suffered from CAU; and 9 (16.1%) were seropositive for Mycoplasma/Chlamydia pneumoniae. The initial symptom severity was moderate-to-severe (UAS7 quartiles 18-32) and comparable between Herpesviridae-seropositive and Herpesviridae-seronegative patients. At 1, 6, and 12 months, UAS7 was consistently higher in seropositive children. In a multivariable analysis (adjusted for age, baseline UAS7, ASST, mean platelet volume, and other serology), Herpesviridae seropositivity was associated with higher UAS scores: mean difference 4.2 score points (95% confidence interval 0.5-7.9; Bayes estimate 4.2, 95% credible interval 1.2-7.3) in a mixed model for repeated measures. This estimate was comparable between children with positive (CAU) and negative (CSU) ASST.
    Conclusion: A history of CMV/EBV/HHV-6 infection might contribute to a slower-resolving CSU in children.
    MeSH term(s) Humans ; Child ; Epstein-Barr Virus Infections ; Bayes Theorem ; Herpesvirus 4, Human ; Chronic Urticaria ; Herpesviridae ; Cytomegalovirus Infections ; Chronic Disease
    Language English
    Publishing date 2023-05-02
    Publishing country Croatia
    Document type Observational Study ; Journal Article
    ZDB-ID 1157623-6
    ISSN 1332-8166 ; 0353-9504
    ISSN (online) 1332-8166
    ISSN 0353-9504
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top